文献速递痛风与晶体性关节病

秋水仙碱使用与痛风患者不良心血管事件之间的关联:一项全国性巢式病例对照研究

Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case-control study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究基于韩国国民健康保险系统全国理赔数据库,纳入2011至2016年间新发痛风且以别嘌醇起始治疗、无动脉粥样硬化性心血管疾病(ASCVD)史的患者,采用巢式病例对照设计,将发生ASCVD事件或ASCVD相关死亡者按年龄、性别、收入、居住地区、合并症及用药与四名对照匹配。结果显示,与未使用秋水仙碱者相比,较高累积限定日剂量(cDDD)与ASCVD事件风险升高相关,且ASCVD事件与ASCVD相关死亡分别分析时结果相似。

要点

  • 与未使用秋水仙碱者相比,cDDD<90、80-179及≥180的OR(95%CI)分别为1.09(1.04,1.15)、1.20(1.07,1.33)、1.21(1.09,1.35)。
  • 秋水仙碱较高cDDD与ASCVD事件几率之间呈曲线关系。
  • ASCVD事件与ASCVD相关死亡分别分析时关联相似;结论认为秋水仙碱使用与新诊断痛风患者ASCVD风险升高相关。

核心结论

  • 在新诊断且无ASCVD史的痛风患者中,秋水仙碱使用与ASCVD风险升高相关。

研究设计与样本

  • 全国性巢式病例对照研究,使用韩国国民健康保险系统全国理赔数据库。
  • 初筛2011至2016年间新发痛风、以别嘌醇为一线治疗起始且无ASCVD史的患者。
  • 随访期间发生ASCVD事件或ASCVD相关死亡者按年龄、性别、收入、居住地区、合并症及用药与四名对照匹配。
  • 主要暴露为秋水仙碱使用,以累积限定日剂量(cDDD)和累积持续时间评估。

主要发现

  • 共9346例发生ASCVD事件或ASCVD相关死亡的患者与35070名对照匹配,患者人群以男性为主。
  • 与未使用者相比,秋水仙碱cDDD<90的OR(95%CI)为1.09(1.04,1.15)。
  • 与未使用者相比,秋水仙碱cDDD 80-179的OR(95%CI)为1.20(1.07,1.33)。
  • 与未使用者相比,秋水仙碱cDDD≥180的OR(95%CI)为1.21(1.09,1.35)。
  • ASCVD事件与ASCVD相关死亡分别分析时关联相似。

关键数值与推荐

  • 秋水仙碱cDDD<90 vs 未使用者:OR 1.09(95%CI 1.04,1.15)。
  • 秋水仙碱cDDD 80-179 vs 未使用者:OR 1.20(95%CI 1.07,1.33)。
  • 秋水仙碱cDDD≥180 vs 未使用者:OR 1.21(95%CI 1.09,1.35)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The association between colchicine use and the primary prevention of atherosclerotic cardiovascular disease (ASCVD) remains unknown. This study aimed to explore the association between colchicine use and new development of ASCVD and ASCVD-related mortality in patients with incident gout. METHODS: This nested case-control study utilized the nationwide claims database of the Korean National Health Insurance System. Patients without a history of ASCVD who developed incident gout and were newly started on allopurinol as first-line therapy between 2011 and 2016 were initially screened. Individuals who experienced ASCVD event or ASCVD-related mortality during the follow-up period were matched with four controls for age, sex, income, residential area, co-morbidities and medications. The main exposure was colchicine use, assessed by (i) the cumulative defined daily doses (cDDDs) and (ii) the cumulative duration. For secondary analyses, the risk of ASCVD events and ASCVD-related mortality were examined separately. RESULTS: Overall, 9346 patients with ASCVD event or ASCVD-related mortality were matched with 35 070 controls. The patient population was predominantly male. Compared with non-users, a curvilinear relationship between higher cDDDs of colchicine and the odds of ASCVD event was observed; the odds ratios (95% CI) were 1.09 (1.04, 1.15) for <90 cDDDs, 1.20 (1.07, 1.33) for 80-179 cDDDs and 1.21 (1.09, 1.35) for ≥180 cDDDs. This association was similarly observed for ASCVD events and ASCVD-related mortality. CONCLUSION: Colchicine use was associated with an increased risk of ASCVD in patients with newly diagnosed gout who did not have a prior history of ASCVD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kim HW, Kang M, Lim H, et al. Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case-control study. Rheumatology (Oxford). 2025. PMID: 39392785. doi:10.1093/rheumatology/keae545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。